Navigation Links
Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Date:11/1/2007

DURHAM, N.C., Nov. 1 /PRNewswire/ -- Regado Biosciences today announced the enrollment of the first patient in a multi-center, open-label, randomized Phase IIa clinical study, named REVERSAL-PCI, of its REG1 Anticoagulation System. The patient was enrolled at Black Hills Cardiology in Rapid City, SD. The study will enroll 26 patients undergoing elective Percutaneous Coronary Intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting on patients at low-risk for complications associated with therapy-related bleeding or heart attack. The REG1 Anticoagulation System is a combination of RB006, an intravenous anticoagulant, and its highly specific, rapidly acting antidote, RB007.

All patients will be pretreated with clopidogrel and aspirin to inhibit platelet activity. Primary procedural success will be defined by absence of significant bleeding events up to hospital discharge or 48 hours post stenting, and by absence of death, nonfatal heart attack, or need to repeat revascularization up to day 14. The study will be conducted at sites in the United States and Argentina.

"There is a significant and immediate need for an anticoagulant therapy that can be adjusted quickly and easily based on the changing medical condition of the patient. Our Phase I studies in healthy volunteers and in patients with stable coronary artery disease showed REG1 provided a safe, potent, and quickly reversible anticoagulant effect," stated Douglas Gooding, Chief Executive Officer of Regado Biosciences. "Our plan is to build on our existing data set and initiate several additional Phase II studies to establish proof of concept in a wide range of coronary revascularization procedures."

Regado has conducted three Phase I clinical studies of REG1, all of which demonstrated the anticoagulation system is safe and the antidote effective in both healthy volunteers and in older pati
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... TARRYTOWN, N.Y. , May 23, 2013 /PRNewswire/ ... reconstruction following mastectomy is an appropriate option ... mutations seeking to surgically reduce their breast cancer ... involves a gradual expansion process and a second ... of implants in the same surgery as mastectomy ...
(Date:5/23/2013)... -- Net Medical Xpress Solutions, Inc., (OTC QB: NMXS), a ... has signed a letter of intent to acquire MedTel ... Huntsville, AL . MedTel Solutions is a physician ... of telemedicine physicians. Consideration for the acquisition will be ... expected by June 30, 2013. Dick Govatski, ...
(Date:5/23/2013)... AVIV, Israel , May 23, 2013 ... BrainTech Israel 2013 , Israel,s ... place on October 14 th -15 th in ... nd most innovative city in the world by the ... "Start-up Nation." BrainTech Israel 2013 will showcase the ...
Breaking Medicine Technology:Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... Stem Cell Sciences From University of Cambridge ... - ("Stem Cell Sciences", "SCS", "the Company"), ... STEM, ASX: STC), a company focused on the commercialisation ... paper describing a technique,for reprogramming adult mammalian cells into ...
... Sourced from China Shows Strong Results Presented at ... Cambridge Healthtech Institute Fall Conference, BOSTON, ... Bioscience International (HUYA) today described the,preclinical profile and outcome ... China by Chipscreen Biosciences, Ltd. of Shenzhen. The,clinical trial ...
Cached Medicine Technology:Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 2Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 3Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer 2Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer 3Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer 4Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer 5
(Date:5/23/2013)... CT (PRWEB) May 23, 2013 Six ... a million dollars by Lyme Research Alliance, the nation's ... major academic institutions. The studies focus on the epidemiology of, ... diseases.  , “LRA is proud to support the ... and the brightest men and women in the field ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Elegance for a woman ... her flair, her taste, her intrigue can often be found in ... gateway to a woman's soul is through her eyes. It ... who she is! That is why the elegance of a woman ... . , Women today, more than any other time, utilize eyewear ...
(Date:5/23/2013)... Looking for tips on how to avoid ... of caring for your aging parent? Today the ... released the results of a survey of 335 geriatric care ... , Here are the top 5 tips identified by these ... survey respondents selecting each option): , 1.    Give each family member ...
(Date:5/23/2013)... Sika Sarnafil , the worldwide market leader ... Roof Systems of Iowa as the Recycling Project of ... during the re-roofing of the SuperTarget retail store in ... Elite contractor and one of Target’s Preferred Tier One ... sustainable building practices and they are a worthy recipient ...
(Date:5/23/2013)... According to a April 18, 2013 ... Found in Everyday Items Can Inhibit Fat Storage,” found ... as cosmetics and other products curb the storage of ... men and women who use such products experience accelerated ... wrinkles earlier than they otherwise would have (Go ...
Breaking Medicine News(10 mins):Health News:Six Investigators Awarded Lyme Research Alliance Grants 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 4Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2Health News:New Survey of Aging Experts Gives Top 5 Tips for Avoiding Family Feud when Caring for Aging Parents 2Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2Health News:Aging and Wrinkles – Gold Found in Everyday Products Can Accelerate the Visual Signs of Aging 2
... a day after two minors died minutes after receiving ... district of Chhattisgarh. ,Two brothers, Umashanker, 6 years, ... they received injections for treatment of fever, cough and ... other members of the same family, who were also ...
... (also known as NRP104 or LDX) by Shire plc ... yielded a good response in children with Attention Deficit ... data was presented at a national meeting of child ... done on 269 children between 6 and 12 who ...
... from the University of California at Los Angeles (UCLA) ... resonance imaging (MRI) scan using the internet by an ... the remote scans were better in quality than the ... technology would benefit areas with inadequate staff members and ...
... farms with genetically modified papaya has led to suing ... called Greenpeace. ,Greenpeace is to take legal ... supply of genetically engineered papaya seeds to farmers throughout ... genetic engineering campaigner for Green Peace Southeast Asia, said, ...
... of harmful chemicals that may be present in some fish, ... ,Following the study of toxic substances in Puget Sound fish, ... Chinook salmon. ,Their study revealed that that Chinook ... mercury and PCBs, which is a banned industrial chemical. ...
... smoking cessation therapy used to help reduce adverse events ... of death for smokers admitted to// the intensive care ... 2006, the 72nd annual international scientific assembly of the ... smokers admitted to the ICU who received nicotine replacement ...
Cached Medicine News:Health News:Smoking Cessation Therapy May be Harmful for ICU Patients 2
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Medicine Products: